The news: Pfizer ended development of its once-daily weight loss pill, danuglipron, after a trial participant experienced a liver injury that may have been caused by the drug.
Yes, and: It’s not the first setback Pfizer has suffered in its aim to capture share of the weight-loss drug market. The drugmaker discontinued a twice-daily oral candidate in 2023 due to tolerability issues experienced by clinical trial patients.
In its latest trial, Pfizer noted that the patient’s liver issue was resolved after they stopped taking danuglipron. The company discontinued the experiment after reviewing clinical data.